![Table 1 from Tolerability and Feasibility of Beta-Blocker Titration in HFpEF Versus HFrEF: Insights From the CIBIS-ELD Trial. | Semantic Scholar Table 1 from Tolerability and Feasibility of Beta-Blocker Titration in HFpEF Versus HFrEF: Insights From the CIBIS-ELD Trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/67c0797707e78e220989e461b8072db79ed1fb0a/5-Table1-1.png)
Table 1 from Tolerability and Feasibility of Beta-Blocker Titration in HFpEF Versus HFrEF: Insights From the CIBIS-ELD Trial. | Semantic Scholar
25 Supplementary tables Supplementary table 1: Conversion table RAS- and beta-blocker Adapted from Schmidt et al. 16
![Cost-effectiveness analysis of nebivolol and metoprolol in essential hypertension: A pharmacoeconomic comparison of antihypertensive efficacy of beta blockers Cost-effectiveness analysis of nebivolol and metoprolol in essential hypertension: A pharmacoeconomic comparison of antihypertensive efficacy of beta blockers](https://ijp-online.com/articles/2014/46/5/images/Indian%20J%20Pharmacol_2014_46_5_485_140577_t2.jpg)
Cost-effectiveness analysis of nebivolol and metoprolol in essential hypertension: A pharmacoeconomic comparison of antihypertensive efficacy of beta blockers
![Tratamiento con betabloqueantes en pacientes con disfunción sistólica ventricular pulmonar obstructiva crónica en medio ambulatorio Tratamiento con betabloqueantes en pacientes con disfunción sistólica ventricular pulmonar obstructiva crónica en medio ambulatorio](https://scielo.isciii.es/img/revistas/pharmacy/v7n4/205-212_04.gif)
Tratamiento con betabloqueantes en pacientes con disfunción sistólica ventricular pulmonar obstructiva crónica en medio ambulatorio
![Comparación del cumplimiento de las guías para fallo cardíaco crónico sistólico en dos clínicas ambulatorias Comparación del cumplimiento de las guías para fallo cardíaco crónico sistólico en dos clínicas ambulatorias](https://scielo.isciii.es/img/revistas/pharmacy/v8n1/original6_t2.gif)
Comparación del cumplimiento de las guías para fallo cardíaco crónico sistólico en dos clínicas ambulatorias
Switching to once-daily evidence-based [beta]-blockers in patients with systolic heart failure or left ventricular dysfunction after myocardial infarction - Document - Gale OneFile: Health and Medicine
![From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5) - ScienceDirect From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5) - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0735109719354567-fx1.jpg)
From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5) - ScienceDirect
![Table 1 from Heart Rate or Beta-Blocker Dose? Association With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction: Results From the HF-ACTION Trial. | Semantic Scholar Table 1 from Heart Rate or Beta-Blocker Dose? Association With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction: Results From the HF-ACTION Trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/d74cb01d7491e0648e608b1b314629930ea1a050/3-Table1-1.png)